Curie Therapeutics is a fully integrated, next-generation radiopharmaceuticals company focused on pioneering a new class of targeted radiopharmaceuticals that are both safe and effective.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/01/21 | $75,000,000 | Series A |
Access Biotechnology Atlas Venture  RA Capital Management | undisclosed |
